Administration of neutralizing anti-S100A9 in a mouse model of ulcerative colitis was reported to significantly reduce inflammatory cytokine production and immune cells infiltrates, with the same antibodies also exerting a protective effect in an azoxymethane/DSS-induced colitis-associated cancer mouse model [179]. This evidence concerns the gene S100A9 and cancer.